Loading news article.

FilingSEC EDGAR8-K

Quoin Pharmaceuticals Receives FDA Fast Track Designation for QRX003

Sep 22, 2026, 16:15 ET · SEC accepted

StagePhase 2/3 preparation

Filing content

Quoin Pharmaceuticals has been granted FDA Fast Track Designation for its QRX003 candidate for the treatment of Peeling Skin Syndrome. The company plans to initiate a Phase 2/3 study in the second half of 2026.

AI summary of the filing. Please also check the source.

Related companies

Quoin Pharmaceuticals Ltd.QNRXView stock

Analyzed by WAPE AI.

Preparing English content…

Repost

Comments —

Loading comments…